- Home
- IVT vs IMVT Comparison
IVT vs IMVT Comparison
Compare IVT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- IMVT
- Stock Information
- Founded
- IVT 2005
- IMVT 2018
- Country
- IVT United States
- IMVT United States
- Employees
- IVT N/A
- IMVT N/A
- Industry
- IVT Real Estate Investment Trusts
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVT Real Estate
- IMVT Health Care
- Exchange
- IVT Nasdaq
- IMVT Nasdaq
- Market Cap
- IVT 2.3B
- IMVT 2.7B
- IPO Year
- IVT N/A
- IMVT N/A
- Fundamental
- Price
- IVT $27.51
- IMVT $16.00
- Analyst Decision
- IVT Buy
- IMVT Buy
- Analyst Count
- IVT 5
- IMVT 10
- Target Price
- IVT $32.75
- IMVT $33.38
- AVG Volume (30 Days)
- IVT 473.7K
- IMVT 1.7M
- Earning Date
- IVT 10-28-2025
- IMVT 11-06-2025
- Dividend Yield
- IVT 3.46%
- IMVT N/A
- EPS Growth
- IVT 1533.99
- IMVT N/A
- EPS
- IVT 1.47
- IMVT N/A
- Revenue
- IVT $287,075,000.00
- IMVT N/A
- Revenue This Year
- IVT $9.70
- IMVT N/A
- Revenue Next Year
- IVT $8.25
- IMVT N/A
- P/E Ratio
- IVT $18.65
- IMVT N/A
- Revenue Growth
- IVT 9.17
- IMVT N/A
- 52 Week Low
- IVT $25.21
- IMVT $12.72
- 52 Week High
- IVT $31.65
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- IVT 27.11
- IMVT 50.79
- Support Level
- IVT $29.27
- IMVT $15.81
- Resistance Level
- IVT $30.20
- IMVT $17.15
- Average True Range (ATR)
- IVT 0.42
- IMVT 0.73
- MACD
- IVT -0.24
- IMVT 0.10
- Stochastic Oscillator
- IVT 7.50
- IMVT 57.98
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.